Please assess the completion status of the following clinical trial:

Trial Title: Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Postoperative Pain After Craniotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for elective craniotomy for resection of a supratentorial tumour under general anaesthesia;~* American Society of Anesthesiologists (ASA) physical status of I or II;~* Participates required to fix their head in a head clamp intraoperatively;~* Participates with an anticipated fully recovery within 2 hours postoperatively.~Exclusion Criteria:~* History of craniotomy;~* Expected delayed extubation or no plan to extubate;~* Participants who cannot use a patient-controlled analgesia (PCA) device;~* Participants who cannot understand the instructions of a numeral rating scale (NRS) 35 before surgery;~* Extreme body mass index (BMI) (\< 15 or \> 35);~* Allergy to opioids, dexamethasone or ropivacaine;~* History of excessive alcohol or drug abuse, chronic opioid use (more than 2 weeks), or use of drugs with confirmed or suspected sedative or analgesic effects;~* History of psychiatric disorders, uncontrolled epilepsy or chronic headache;~* Pregnant or at breastfeeding;~* Symptomatic cardiopulmonary, renal, or liver dysfunction or history of diabetes;~* Preoperative Glasgow Coma Scale\< 15;~* Suspicion of intracranial hypertension;~* Peri-incisional infection;~* Participants who have received radiation therapy and chemotherapy preoperatively or with a high probability to require a postoperative radiation therapy and chemotherapy according to the preoperative imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone plus Ropivacaine group (Type: EXPERIMENTAL): Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
- Ropivacaine group (Type: ACTIVE_COMPARATOR): Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).